

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

[WSU-HN30](#)

RRID:CVCL_5525

Type: Cell Line

Proper Citation

RRID:CVCL_5525

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5525

Proper Citation: RRID:CVCL_5525

Description: Cell line WSU-HN30 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pharyngeal squamous cell carcinoma

Defining Citation: [PMID:7705939](#), [PMID:8001221](#), [PMID:9049184](#), [PMID:9389571](#), [PMID:21868764](#), [PMID:25275298](#), [PMID:26754630](#), [PMID:28196595](#), [PMID:29156801](#)

Comments: Part of: OPC-22 oral and pharyngeal cancer cell line panel., Part of: MD Anderson Cell Lines Project.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: WSU-HN30

Synonyms: HN30, HN-30, Wayne State University-Head and Neck 30

Cross References: BTO:BTO_0005039, Cosmic:922084, Cosmic:2131844, Cosmic:2296299, GEO:GSM1643583, Wikidata:Q54994487

ID: CVCL_5525

Record Creation Time: 20220427T221724+0000

Record Last Update: 20260905T182802+0000

Ratings and Alerts

No rating or validation information has been found for WSU-HN30.

No alerts have been found for WSU-HN30.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tsai TY, et al. (2026) The SMAC-mimetic xevinapant differentially enhances cisplatin and immune checkpoint blockade efficacy in high-risk HPV-positive tumors. *Translational oncology*, 70, 102839.

Kawabe M, et al. (2026) Targeted suppression of SPP1 inhibits tumor invasion and metastasis in NRF2 hyperactivated cisplatin resistant HNSCC. *Journal of translational medicine*, 24(1).

Yadollahi P, et al. (2025) Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting. *British journal of cancer*, 133(12), 1802.

Liu J, et al. (2025) Targeting PIK3CB/YAP1 improves the sensitivity of paclitaxel by suppressing aging in head and neck squamous tumor cells. *Cancer cell international*, 25(1), 190.

Ji Y, et al. (2024) IL-1?? facilitates GSH synthesis to counteract oxidative stress in oral squamous cell carcinoma under glucose-deprivation. *Cancer letters*, 589, 216833.

Chen X, et al. (2022) Long noncoding RNA Inc-H2AFV-1 promotes cell growth by regulating aberrant m6A RNA modification in head and neck squamous cell carcinoma. *Cancer science*, 113(6), 2071.

Javaid S, et al. (2022) Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. *Molecular cancer therapeutics*, 21(5), 762.

Jiang Y, et al. (2022) lncRNA Inc-POP1-1 upregulated by VN1R5 promotes cisplatin resistance in head and neck squamous cell carcinoma through interaction with MCM5. *Molecular therapy : the journal of the American Society of Gene Therapy*, 30(1), 448.

Gu Z, et al. (2022) Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma. *BMC medicine*, 20(1), 175.